-DOCSTART- -X- O
Korean -X- _ B-Intervention
Red -X- _ I-Intervention
Ginseng -X- _ I-Intervention
( -X- _ I-Intervention
KRG -X- _ I-Intervention
) -X- _ I-Intervention
is -X- _ O
a -X- _ O
functional -X- _ O
food -X- _ O
and -X- _ O
has -X- _ O
been -X- _ O
well -X- _ O
known -X- _ O
for -X- _ O
keeping -X- _ O
good -X- _ O
health -X- _ O
due -X- _ O
to -X- _ O
its -X- _ O
anti-fatigue -X- _ O
and -X- _ O
immunomodulating -X- _ O
activities. -X- _ O
However -X- _ O
, -X- _ O
there -X- _ O
is -X- _ O
no -X- _ O
data -X- _ O
on -X- _ O
Korean -X- _ B-Intervention
red -X- _ I-Intervention
ginseng -X- _ I-Intervention
for -X- _ O
its -X- _ O
preventive -X- _ O
activity -X- _ O
against -X- _ O
acute -X- _ B-Patient
respiratory -X- _ I-Patient
illness -X- _ I-Patient
( -X- _ I-Patient
ARI -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
The -X- _ O
study -X- _ O
was -X- _ O
conducted -X- _ O
in -X- _ O
a -X- _ O
randomized -X- _ O
, -X- _ O
double-blinded -X- _ O
, -X- _ O
placebo-controlled -X- _ O
trial -X- _ O
in -X- _ O
healthy -X- _ B-Patient
volunteers -X- _ I-Patient
( -X- _ O
Clinical -X- _ O
Trial -X- _ O
Number -X- _ O
: -X- _ O
NCT01478009 -X- _ O
) -X- _ O
. -X- _ O
Our -X- _ O
primary -X- _ O
efficacy -X- _ O
end -X- _ O
point -X- _ O
was -X- _ O
the -X- _ O
number -X- _ O
of -X- _ O
ARI -X- _ B-Patient
reported -X- _ O
and -X- _ O
secondary -X- _ O
efficacy -X- _ O
end -X- _ O
point -X- _ O
was -X- _ O
severity -X- _ O
of -X- _ O
symptoms -X- _ O
, -X- _ O
number -X- _ O
of -X- _ O
symptoms -X- _ O
, -X- _ O
and -X- _ O
duration -X- _ O
of -X- _ O
ARI. -X- _ O
A -X- _ O
total -X- _ O
of -X- _ O
100 -X- _ O
volunteers -X- _ O
were -X- _ O
enrolled -X- _ O
in -X- _ O
the -X- _ O
study. -X- _ O
Fewer -X- _ B-Outcome
subjects -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
KRG -X- _ I-Outcome
group -X- _ I-Outcome
reported -X- _ I-Outcome
contracting -X- _ I-Outcome
at -X- _ I-Outcome
least -X- _ I-Outcome
1 -X- _ I-Outcome
ARI -X- _ I-Outcome
than -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
placebo -X- _ I-Outcome
group -X- _ I-Outcome
( -X- _ I-Outcome
12 -X- _ I-Outcome
[ -X- _ I-Outcome
24.5 -X- _ I-Outcome
% -X- _ I-Outcome
] -X- _ I-Outcome
vs -X- _ I-Outcome
22 -X- _ I-Outcome
[ -X- _ I-Outcome
44.9 -X- _ I-Outcome
% -X- _ I-Outcome
] -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.034 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
difference -X- _ I-Outcome
was -X- _ I-Outcome
statistically -X- _ I-Outcome
significant -X- _ I-Outcome
between -X- _ I-Outcome
the -X- _ I-Outcome
two -X- _ I-Outcome
groups. -X- _ I-Outcome
The -X- _ I-Outcome
symptom -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
subjects -X- _ I-Outcome
who -X- _ I-Outcome
experienced -X- _ I-Outcome
the -X- _ I-Outcome
ARI -X- _ I-Outcome
, -X- _ I-Outcome
was -X- _ I-Outcome
similar -X- _ I-Outcome
between -X- _ I-Outcome
the -X- _ I-Outcome
two -X- _ I-Outcome
groups -X- _ I-Outcome
( -X- _ I-Outcome
KRG -X- _ I-Outcome
vs -X- _ I-Outcome
placebo -X- _ I-Outcome
; -X- _ I-Outcome
5.2 -X- _ I-Outcome
± -X- _ I-Outcome
2.3 -X- _ I-Outcome
vs -X- _ I-Outcome
6.3 -X- _ I-Outcome
± -X- _ I-Outcome
5.0 -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.475 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
The -X- _ I-Outcome
symptom -X- _ I-Outcome
scores -X- _ I-Outcome
were -X- _ I-Outcome
low -X- _ I-Outcome
tendency -X- _ I-Outcome
in -X- _ I-Outcome
KRG -X- _ I-Outcome
group -X- _ I-Outcome
( -X- _ I-Outcome
KRG -X- _ I-Outcome
vs -X- _ I-Outcome
placebo -X- _ I-Outcome
; -X- _ I-Outcome
9.5 -X- _ I-Outcome
± -X- _ I-Outcome
4.5 -X- _ I-Outcome
vs -X- _ I-Outcome
17.6 -X- _ I-Outcome
± -X- _ I-Outcome
23.1 -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.241 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
The -X- _ O
study -X- _ O
suggests -X- _ O
that -X- _ O
KRG -X- _ B-Outcome
may -X- _ I-Outcome
be -X- _ I-Outcome
effective -X- _ I-Outcome
in -X- _ I-Outcome
protecting -X- _ I-Outcome
subjects -X- _ I-Outcome
from -X- _ I-Outcome
contracting -X- _ I-Outcome
ARI -X- _ I-Outcome
, -X- _ O
and -X- _ O
may -X- _ O
have -X- _ O
the -X- _ O
tendency -X- _ O
to -X- _ O
decrease -X- _ O
the -X- _ O
duration -X- _ O
and -X- _ O
scores -X- _ O
of -X- _ O
ARI -X- _ O
symptoms -X- _ O
. -X- _ O

